

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Sotatercept for treating pulmonary arterial
hypertension [ID6163]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

The scope consultation and workshop identified that there could be issues of inequitable access to the specialist services required to administer sotatercept. The technology is administered as a pre-filled injection that is to be used at home, but some people (e.g. with disabilities) may need help to administer, e.g from a specialist nurse. But also, some people who have previously not been able to have IV treatment may now be able to access treatment because sotatercept is self-administered at home.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

These do not constitute equalities issues that will need to be explicitly addressed by committee.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Janet Robertson.....

Date: 05/06/2024